The Otsuka and Noven successes from 2018 portend a new era of drug development, one in which treatment efficacy is established in the context of the patient's overall life and behavior. It is time for measurement science to follow and embrace the fact that how we measure outcomes will evolve from applying one solution to finding an empirical basis for a highly customized application of all of them, enabled by technology. Personalized medicine needs a more personalized approach to measurement.
Request a Genetics in Clinical Trials training session
What You'll LearnMost Recent Flipbooks
Q&A with CNS Expert, Dr. Leslie Citrome
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
Q&A with CNS Expert, Dr. Christoph U. Correll
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
CNS Drugs Take Longer to Develop, Win Approval
CNS drugs take 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials
Are Scientists Closing in on Treatments for Schizophrenia's Most Elusive Symptoms?
Researchers, buoyed by a spike in promising clinical trials and tools, believe they may be close to unraveling new ways to treat some of the most insidious yet elusive effects of schizophrenia
IRBs can make the most of central IRB partnerships
The IRB at Inova Health System of Falls Church, VA, began working with a central IRB 15 years ago. Since then, the IRB developed a well-organized process for its partnerships with independent IRBs.
Conquer Study Start-Up Delays With a Data-Driven Approach
